Previous close | 58.80 |
Open | 58.80 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 58.80 - 58.80 |
52-week range | 56.80 - 78.20 |
Volume | |
Avg. volume | 47 |
Market cap | 29.612B |
Beta (5Y monthly) | 0.64 |
PE ratio (TTM) | 30.31 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
DEERFIELD, Ill., May 29, 2024--Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (HF HD). The study, "Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study," was prese
DEERFIELD, Ill., May 23, 2024--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:30 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Monday, December 2, 2024.
Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.